10 September 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave Featured on CNBC's Worldwide Exchange

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated, non-antibiotic infection prevention therapies, announces that its Steriwave^® nasal photodisinfection technology received international media attention when it was highlighted yesterday on CNBC's Worldwide Exchange by former President of Mexico, Vicente Fox.

During the interview, Mr. Fox emphasized the global need to address antibiotic resistance (AMR), particularly in combatting hospital-acquired infections and protecting healthcare workers. He underscored the urgent need for innovative, effective infection-prevention strategies like Steriwave, a cost effective, non-antibiotic therapy that does not generate resistance. He indicated that there is a critical role for light-activated antimicrobial technologies in combating the escalating global threat of multidrug-resistant infections, especially in developing nations where, for most people, access to medicine and healthcare is limited.

Dr. Nicolas Loebel, President and CTO of Ondine Biomedical, stated:

"We are pleased that Steriwave photodisinfection and the urgent issue of antimicrobial resistance were both spotlighted on CNBC's Worldwide Exchange. This recognition underscores our leadership advancing non-antibiotic infection-prevention solutions and our global mission to deliver simple solutions to combat complex multidrug-resistant infections."

As previously announced on August 11, 2025, President Fox is serving as Chair of the Light Against AMR Initiative, a strategic program co-sponsored by Ondine Biomedical and the International Photodynamic Association. The Light Against AMR Initiative is dedicated to accelerating the deployment of affordable, light-based infection control technologies in fast-growing, underserved, and emerging markets worldwide.

Enquiries:

Correction note: During the broadcast, Mr. Fox was introduced and at one point referred to himself as a member of Ondine's Board of Directors. This was in error. Mr. Fox is not a member of Ondine's Board.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.